(PharmaNewsWire.Com, August 11, 2021 ) The Key Growth Elements in Detailed?
The growth of Glycobiology Market is majorly driven by the increasing research activities on glycomics, rising R&D investments in pharmaceutical and biotechnology companies, growth in the proteomics market. On the other hand, emerging countries such as India and China providing lucrative opportunities for players operating in this segment. However, the high cost of tools is expected to hamper the market growth to a certain extent during the forecast period.
Worldwide Growth Opportunities in Terms of Revenue:
The Global Glycomics Market is estimated to grow from USD 1.0 billion in 2020 to USD 2.0 billion by 2025, at a CAGR of 13.8%.
The enzymes segment accounted for the largest share of the Glycobiology Market.
By enzymes, has been categorized into five product segments, namely, enzymes, instruments, kits, carbohydrates, and reagents & chemicals. The enzymes segment is expected to dominate the market in 2020 and is projected to grow at the highest CAGR during the forecast period. The large share and high growth of this segment can be attributed to the consumable nature of enzymes and their wide applications in a variety of R&D and drug discovery procedures.
Glycomics market for drug discovery & development application is expected to grow at a high rate.
By application, segmented into drug discovery & development, disease diagnostics, and other applications. Drug discovery & development is the largest and the fastest-growing application segment in the glycomics market, majorly due to the increasing R&D investments in pharmaceutical and biotechnology companies and the growing number of drug discovery research activities in academic research institutes.
The global glycomics market is segmented into North America (US and Canada), Europe (Germany, the UK, France, Italy, Spain, and the Rest of Europe), Asia Pacific (Japan, China, India, Australia, and the Rest of Asia Pacific), and the Rest of the World (Latin America and the Middle East and Africa). In 2020, North America is expected to dominate the global Glycobiology Market, followed by Europe. The largest share of North America is mainly attributed to increasing funding on glycomics research, rising R&D expenditure for drug discovery & development, and the presence of all key players.
Major Key Players Mentioned in the research report are:
The prominent players operating in the glycomics market include Merck KGaA (Germany), Agilent Technologies (US), Thermo Fisher Scientific (US), New England Biolabs (US), Shimadzu Corporation (Japan), Takara Bio (Japan), S-BIO (subsidiary of Sumitomo Bakelite Co. Ltd., Japan), Waters Corporation (US), Asparia Glycomics S.L. (Spain), Bio-Techne (US), Bruker Corporation (US), Danaher Corporation (US), RayBiotech (US), Z Biotech (US), Chemily Glycoscience (US), Dextra Laboratories (UK), Lectenz Bio (US), and Ludger Ltd. (UK).
Recent Developments in Glycobiology Market:
- In June 2019, Agilent Technologies (US) has launched InfinityLab LC/MSD iQ System
- In June 2018, Thermo Fisher Scientific (US) had launched UHMR Hybrid Quadrupole-Orbitrap Mass Spectrometer.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
